Mexican Biosimilar Filgrastim for Autologous Hematopoietic Stem Cell Mobilization and Transplantation
- Autores: Mónica León González, Andrés Aurelio León Peña, María Fernanda Vallejo Villalobos, Ana Karen Núñez Cortés, Alejandro Ruiz Argüelles, Guillermo José Ruiz Argüelles
- Localización: Revista de investigación clínica, ISSN 0034-8376, ISSN-e 2564-8896, Vol. 68, Nº. 4, 2016, págs. 181-183
- Idioma: inglés
- Enlaces
-
Resumen
Background: Following the release of the initial presentation of filgrastim (granulocyte colony-stimulating factor), several biosimilars have been developed worldwide. Objective: To study the efficacy of a Mexican biosimilar granulocyte colony-stimulating factor in a single transplant center. Methods: In a group of 19 consecutive patients with multiple sclerosis given autografts, we employed granulocyte colony-stimulating factors to mobilize stem cells from the bone marrow to the peripheral blood, either the original granulocyte colony-stimulating factor (n = 10) or a Mexican granulocyte colony-stimulating factor biosimilar (n = 9).
Results: The efficacy of both agents was similar in mobilization capacity, white blood cell count rise, stem cell collection, and kinetics of auto-engraftment. Conclusion: We conclude that both granulocyte colony-stimulating factor agents were similar in their efficacy to mobilize stem cells and usefulness in autografts. (REV INVES CLIN. 2016;68:181-3)
